Global HEOR Bayer Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516, USA.
Expert Rev Pharmacoecon Outcomes Res. 2005 Aug;5(4):457-66. doi: 10.1586/14737167.5.4.457.
A better understanding of how antimicrobial therapies affect the total cost of lower uncomplicated urinary tract infection, including direct (e.g., doctor visits), indirect (e.g., productivity) and intangible (e.g., pain) costs would facilitate selection of an optimal therapeutic approach. The results of this literature review indicate that the there is a considerable societal burden from uncomplicated urinary tract infection, with approximately USD 1 billion in indirect and over USD 600 million in direct costs in 1995. However, no single identified study incorporated all three cost components, there are gaps in the knowledge concerning the current extent of these costs, and there are no comparative assessments based on total cost. Research is needed to provide current insights on the burden of uncomplicated urinary tract infection in terms of direct, indirect and intangible costs.
更好地了解抗菌治疗如何影响下尿路感染的总成本，包括直接（例如，医生就诊）、间接（例如，生产力）和无形（例如，疼痛）成本，将有助于选择最佳治疗方法。本文献综述的结果表明，下尿路感染会给社会带来相当大的负担，1995 年间接成本约为 10 亿美元，直接成本超过 6 亿美元。然而，没有一项单独的研究纳入了所有三个成本组成部分，目前这些成本的范围还存在知识空白，也没有基于总成本的比较评估。需要进行研究，提供下尿路感染直接、间接和无形成本负担的最新见解。
